Wei Fu
Executive ChairmanMr. Wei Fu serves as Chief Executive Officer at CBC Group.He has several years of private equity experience, and oversees the firm’s overall strategy, investment activities, talent development and assumes the responsibilities in maintaining the firm’s long-term partnership with global investors. He has personally led several of the firm’s investment transactions and was instrumental in incubating a number of biotech and pharmaceutical companies. He is Director of I-Mab from June 2018 and served as its Chairman from July 2024 to September 2025, serves as Executive Chairman since September 2025. He is Director of Ascletis BioScience Co., Ltd from September 2015. He joined the Ascletis BioScience Co., Ltd on September 02, 2015. He was Executive Chairman of Everest Medicines Limited until October 10, 2025 and serves as its Non-Executive Director since October 10, 2025. He is Co-Owner of Summit Healthcare Acquisition Sponsor LLC. He was Non-Executive Director of Ascletis Pharma Inc. from April 27, 2018 to December 24, 2018. He was employed at Ascletis Pharma Inc. from September 2015 to December 24, 2018. Mr. Fu was awarded as "Top 30 Best Private Equity Investors in 2023-2024" by Investorcn.com. Before founding CBC Group in early 2014, he was the General Manager of Far East Horizon’s Investments Group, where he recruited and managed a team of over 10 investment professionals, overseeing investments of various sectors. Prior to this, he was the head of the Beijing office and Partner at Themes Investment. Earlier in his career he worked at Macquarie Group, Standard Chartered Bank and Goldman Sachs and was one of the earliest private equity professionals in China when he started his career at Temasek in 2004 and was involved in private equity investments ranging from financial institutions, real estate, consumer to TMT. Where he was a Ministry of Education scholar. Wei is a member of the prestigious Young Presidents’ Organization. He has Bachelor's in Business Administration & Electrical Engineering from Nanyang Technological University in 2005.
Positions
- Company NameNovaBridge BiosciencesStock CodeNBPPositionExecutive Chairman
